NovaBridge Biosciences (NBP) EBIT Margin (2019 - 2023)
NovaBridge Biosciences (NBP) posted quarterly EBIT Margin of 789260.0% for Q4 2023, down 23279.43% on a QoQ basis from 3375.87% in Q3 2023.
NovaBridge Biosciences (NBP) EBIT Margin (2019 - 2023) Analysis & Trends
NovaBridge Biosciences (NBP) has reported EBIT Margin for 3 consecutive years, with 789260.0% the latest figure, recorded in Q4 2023.
- Quarterly EBIT Margin changed N/A year-over-year to 789260.0% in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 4903.88% (changed N/A YoY) and the FY2023 annual result came in at 27673.99%, down 982002.0% from the prior year.
- EBIT Margin eased to 789260.0% in Q4 2023 per NBP's latest filing, from 3375.87% in the prior quarter.
- Over the last five years, EBIT Margin for NBP reached as high as 5927.05% in Q4 2020 and fell as low as 789260.0% in Q4 2023.
- A 3-year average of 159266.08% and a median of 3375.87% in 2023 frame the typical range for EBIT Margin.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | NovaBridge Biosciences | 389.86 Mn | 389.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -789,260.00% |
| Sep 30, 2023 | -3,375.87% |
| Jun 30, 2023 | -7,578.62% |
| Dec 31, 2020 | 5,927.05% |
| Sep 30, 2019 | -2,042.94% |